I Olarte Carrillo1, C Ramos Peñafiel2, E Miranda Peralta1, E Rozen Fuller2, J J Kassack Ipiña2, F Centeno Cruz3, E Garrido Guerrero4, J Collazo Jaloma2, K Nacho Vargas5, A Martínez Tovar1. 1. a Laboratorio de Biología Molecular , Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga" , Ciudad de México , Mexico. 2. b Servicio de Hematología. Hospital General de México "Dr. Eduardo Liceaga" , Ciudad de México , Mexico. 3. c Laboratorio de Immunogenómica y Enfermedades Metabólicas , Instituto Nacional de Medicina Genómica , Secretaria de Salud, Ciudad de México , Mexico. 4. d Departamento de Genética y Biología Molecular , Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV) , Ciudad de México , Mexico. 5. e Oncología Médica Novartis, Novartis Farmacéutica SA , Ciudad de México , Mexico.
Abstract
OBJECTIVES: Acute lymphoblastic leukemia (ALL) is a clonal disease that accounts for 20% of acute leukemias in adults. A high percentage of adult patients (ranging from 70 to 80%) reach complete remission; however, the 5-year survival rate is only 20-40%. One of the main obstacles to treatment success is the drug resistance of leukemic cells. Therefore, our research group analyzed the ABCB1 and ABCG2 gene expression levels in 61 patients diagnosed with ALL and assessed whether the levels affected the clinical parameters and 40-month survival rate. METHODS: The ABCB1 and ABCG2 gene expression levels were analyzed using real-time polymerase chain reaction in 61 patients diagnosed with ALL and 99 healthy donors as controls. The association between ABCB1 and ABCG2 gene expression levels and clinical variables was determined using the Chi-square test and Fisher's exact test. Overall survival (OS) was determined using the Kaplan-Meier method. RESULTS: The results showed high ABCB1 and ABCG2 gene levels, which were 4.5 and 2.3 times the levels of healthy donors, respectively. A total of 52% of the study patients expressed high ABCB1 levels and were significantly associated with the high-risk patient group and a decreased 40-month survival rate of 78%. Only 49% of the patients expressed high ABCG2 gene levels. No association was found between the clinical parameters and the ABCG2 gene expression levels. CONCLUSIONS: Early detection of ABCB1 gene expression levels could be important for the diagnosis and monitoring of ALL patients.
OBJECTIVES:Acute lymphoblastic leukemia (ALL) is a clonal disease that accounts for 20% of acute leukemias in adults. A high percentage of adult patients (ranging from 70 to 80%) reach complete remission; however, the 5-year survival rate is only 20-40%. One of the main obstacles to treatment success is the drug resistance of leukemic cells. Therefore, our research group analyzed the ABCB1 and ABCG2 gene expression levels in 61 patients diagnosed with ALL and assessed whether the levels affected the clinical parameters and 40-month survival rate. METHODS: The ABCB1 and ABCG2 gene expression levels were analyzed using real-time polymerase chain reaction in 61 patients diagnosed with ALL and 99 healthy donors as controls. The association between ABCB1 and ABCG2 gene expression levels and clinical variables was determined using the Chi-square test and Fisher's exact test. Overall survival (OS) was determined using the Kaplan-Meier method. RESULTS: The results showed high ABCB1 and ABCG2 gene levels, which were 4.5 and 2.3 times the levels of healthy donors, respectively. A total of 52% of the study patients expressed high ABCB1 levels and were significantly associated with the high-risk patient group and a decreased 40-month survival rate of 78%. Only 49% of the patients expressed high ABCG2 gene levels. No association was found between the clinical parameters and the ABCG2 gene expression levels. CONCLUSIONS: Early detection of ABCB1 gene expression levels could be important for the diagnosis and monitoring of ALL patients.
Authors: Mohammad Ali Esmaili; Ahmad Kazemi; Mohammad Faranoush; Hakan Mellstedt; Farhad Zaker; Majid Safa; Narjes Mehrvar; Mohammad Reza Rezvany Journal: Iran J Basic Med Sci Date: 2020-06 Impact factor: 2.699
Authors: Irma Olarte Carrillo; Christian Omar Ramos Peñafiel; Iveth Mendoza Salas; Rafael Cerón Maldonado; Anel Irais García Laguna; Adrián De la Cruz Rosas; Carlos Martinez Murrillo; Adolfo Martinez Tovar Journal: Infect Drug Resist Date: 2022-05-24 Impact factor: 4.177
Authors: Kateryna Petrykey; Aziz M Rezgui; Mathilde Le Guern; Patrick Beaulieu; Pascal St-Onge; Simon Drouin; Laurence Bertout; Fan Wang; Jessica L Baedke; Yutaka Yasui; Melissa M Hudson; Marie-Josée Raboisson; Caroline Laverdière; Daniel Sinnett; Gregor U Andelfinger; Maja Krajinovic Journal: Pharmacogenomics Date: 2021-09-10 Impact factor: 2.638
Authors: Christian Ramos-Peñafiel; Irma Olarte-Carrillo; Rafael Cerón-Maldonado; Etta Rozen-Fuller; Juan Julio Kassack-Ipiña; Guillermo Meléndez-Mier; Juan Collazo-Jaloma; Adolfo Martínez-Tovar Journal: J Transl Med Date: 2018-09-03 Impact factor: 5.531
Authors: Irma Olarte Carrillo; Anel Irais García Laguna; Adrián De la Cruz Rosas; Christian Omar Ramos Peñafiel; Juan Collazo Jaloma; Adolfo Martínez Tovar Journal: BMC Med Genomics Date: 2021-10-26 Impact factor: 3.063
Authors: Judit C Sági; András Gézsi; Bálint Egyed; Zsuzsanna Jakab; Noémi Benedek; Andishe Attarbaschi; Stefan Köhrer; Jakub Sipek; Lucie Winkowska; Marketa Zaliova; Stavroula Anastasopoulou; Benjamin Ole Wolthers; Susanna Ranta; Csaba Szalai; Gábor T Kovács; Ágnes F Semsei; Dániel J Erdélyi Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639